Bigbear Pharmaceutical·Medication Guide

• What Does Binimetinib Treat? Indications and Therapeutic Effects of Binimetinib

  Binimetinib is indicated for use in combination with encorafenib for the treatment of advanced melanoma and non-small cell lung cancer (NSCLC) harbori···【Read More】

  Update: 2026-05-12Source: Haiou HealthViews: 136

• FDA Approves Cabozantinib for Previously Treated Patients with Advanced Neuroendocrine Tumors

  March 26, 2025--Alameda, CA--(BUSINESS WIRE)Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approve···【Read More】

  Update: 2026-05-11Source: Haiou HealthViews: 170

• FDA Approves Cabozantinib for Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

  September 17, 2021--Alameda, CA--(BUSINESS WIRE)Exelixis, Inc. (NASDAQ: EXEL) announced that the U.S. Food and Drug Administration (FDA) has approved ···【Read More】

  Update: 2026-05-11Source: Haiou HealthViews: 132

• FDA Approves Nivolumab in Combination with Cabozantinib as First-Line Treatment for Advanced Renal Cell Carcinoma

  January 22, 2021--Princeton, NJ--(BUSINESS WIRE)Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approv···【Read More】

  Update: 2026-05-11Source: Haiou HealthViews: 152

• ​FDA Approves Cabozantinib Tablets for the Treatment of Previously Treated Hepatocellular Carcinoma

  January 14, 2019--Alameda, CA--(BUSINESS WIRE)Exelixis, Inc. (Nasdaq: EXEL) announced that the U.S. Food and Drug Administration (FDA) has approved ca···【Read More】

  Update: 2026-05-11Source: Haiou HealthViews: 142

• FDA Approves Cabozantinib Tablets for Previously Untreated Advanced Renal Cell Carcinoma

  December 19, 2017 — South San Francisco, CA — (Business Wire)Exelixis, Inc. (NASDAQ: EXEL) announced that the U.S. Food and Drug Administration (FDA) ···【Read More】

  Update: 2026-05-11Source: Haiou HealthViews: 137

• FDA Approves Cabozantinib for Treatment of Previously Treated Advanced Neuroendocrine Tumors

  March 31, 2025 (HealthDay) — According to a press release issued by the Dana-Farber Cancer Institute:The U.S. Food and Drug Administration (FDA) has a···【Read More】

  Update: 2026-05-09Source: Haiou HealthViews: 137

• Is Cabozantinib a Chemotherapy Drug?

  Cabozantinib is not a chemotherapy drug; rather, it is a targeted therapy medication. It works by targeting specific enzymes that are typically closel···【Read More】

  Update: 2026-05-09Source: Haiou HealthViews: 137

• Can Cabozantinib Cure Cancer?

  Cabozantinib cannot cure cancer. Cabozantinib is a tyrosine kinase inhibitor that is currently approved for the treatment of the following types of ca···【Read More】

  Update: 2026-05-09Source: Haiou HealthViews: 154

• Mechanism of Action of Enasidenib for the Treatment of Acute Myeloid Leukemia (AML)

  Enasidenib is an oral targeted therapy used for acute myeloid leukemia (AML) that exerts its effects by blocking isocitrate dehydrogenase-2 (IDH2).Mec···【Read More】

  Update: 2026-05-09Source: Haiou HealthViews: 142

• Enasidenib: Uses, Mechanism of Action, and Indications

  Enasidenib is an oral medication used to treat acute myeloid leukemia (AML) in adult patients. Acute myeloid leukemia (AML) is a type of cancer that a···【Read More】

  Update: 2026-05-09Source: Haiou HealthViews: 155

• ​FDA Approves Enasidenib for Relapsed or Refractory Acute Myeloid Leukemia with IDH2 Mutation

  August 1, 2017 — The U.S. Food and Drug Administration (FDA) has approved Enasidenib for the treatment of adult patients with relapsed or refractory a···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 156

• FDA Warns That Leukemia Drug Enasidenib May Trigger Differentiation Syndrome

  On November 29, 2018, the U.S. Food and Drug Administration (FDA) issued a warning stating that signs and symptoms of a life-threatening side effect k···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 150

• Anagrelide: Prescription Information and Overview

  Anagrelide capsules, for oral administration, were first approved for marketing in the United States in 1997. Anagrelide is a thrombocytopenic agent i···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 174

• FDA Approves Osimertinib for EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

  On November 16, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to an oral medication for the treatment of patients wit···【Read More】

  Update: 2026-05-08Source: Haiou HealthViews: 175